Entero Therapeutics (NASDAQ:ENTO) Trading 15.5% Higher – Here’s Why

Entero Therapeutics, Inc. (NASDAQ:ENTO) shot up 15.5% on Friday . The company traded as high as $3.23 and last traded at $3.13. 399,212 shares traded hands during mid-day trading, an increase of 216% from the average session volume of 126,532 shares. The stock had previously closed at $2.71.

Entero Therapeutics Stock Performance

The company has a market capitalization of $4.97 million, a PE ratio of -1.85 and a beta of 1.19. The stock has a 50 day moving average price of $3.31 and a two-hundred day moving average price of $3.30.

Hedge Funds Weigh In On Entero Therapeutics

An institutional investor recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC purchased a new stake in Entero Therapeutics, Inc. (NASDAQ:ENTO) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned 0.74% of Entero Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 12.30% of the company’s stock.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.